Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MIBC”

68 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 68 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06623162
What this trial is testing

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Who this might be right for
MibcMuscle Invasive Bladder Cancer
Fundación de investigación HM 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07639983
What this trial is testing

Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma

Who this might be right for
Muscle-Invasive Bladder Cancer (MIBC)Urinary Bladder Cancer
Sheng Tai 44
Testing effectiveness (Phase 2)Looking for participantsNCT06682728
What this trial is testing

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Who this might be right for
Urothelial CarcinomaMuscle-invasive Bladder Cancer
University of California, Irvine 23
Testing effectiveness (Phase 2)Ended earlyNCT02389764
What this trial is testing

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 10
Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Not applicableNot Yet RecruitingNCT07440901
What this trial is testing

Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

Who this might be right for
Muscle-invasive Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT06417190
What this trial is testing

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Who this might be right for
Muscle-Invasive Bladder CarcinomaTumor
Leslie Ballas 20
Testing effectiveness (Phase 2)UnknownNCT04543110
What this trial is testing

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Who this might be right for
Bladder Cancer
Ottawa Hospital Research Institute 16
Testing effectiveness (Phase 2)Study completedNCT03294304
What this trial is testing

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Who this might be right for
Muscle Invasive Bladder Cancer
Masonic Cancer Center, University of Minnesota 43
Not applicableActive Not RecruitingNCT03333356
What this trial is testing

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

Who this might be right for
Patients With High-risk MIBC
UNICANCER 81
Testing effectiveness (Phase 2)Ended earlyNCT03288545
What this trial is testing

Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Who this might be right for
Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic Neoplasms+4 more
Astellas Pharma Global Development, Inc. 348
Testing effectiveness (Phase 2)Ended earlyNCT05041101
What this trial is testing

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Who this might be right for
Breast Inflammatory CarcinomaRecurrent Breast Inflammatory CarcinomaStage IV Breast Inflammatory Carcinoma
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Looking for participantsNCT06511648
What this trial is testing

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Who this might be right for
Muscle-invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT03978624
What this trial is testing

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Who this might be right for
Bladder Cancer
UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04138628
What this trial is testing

Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Who this might be right for
Bladder CancerBladder Cancer, Metastatic
Jørgen Bjerggaard Jensen 154
Not applicableNot Yet RecruitingNCT07529639
What this trial is testing

Tumor Budding and T1 Substaging in Urothelial Bladder Cancer

Who this might be right for
Urothelial Bladder CarcinomaBladder CarcinomaNon-Muscle-Invasive Bladder Cancer (NMIBC)+1 more
Assiut University 100
Very early researchWithdrawnNCT05395260
What this trial is testing

FL- 101 Study in Non-Metastatic MIBC

Who this might be right for
Muscle Invasive Bladder Carcinoma
Flame Biosciences
Testing effectiveness (Phase 2)UnknownNCT05979740
What this trial is testing

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Who this might be right for
Muscle Invasive Bladder CancerHER2 ExpressionRadiotherapy+2 more
RenJi Hospital 6
Large-scale testing (Phase 3)Study completedNCT03924856
What this trial is testing

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 907
Testing effectiveness (Phase 2)Study completedNCT03636256
What this trial is testing

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaUrinary Bladder Neoplasm+6 more
NanOlogy, LLC 36
Load More Results